Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib for Prevention of Relapse and GVHD in Allo-HCT for High-risk Hematologic Malignancies
NCT02145403Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Oct 2014
- Primary completion
- Nov 2018
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib in hematologic malignancy, graft-versus-host disease (GVHD), sponsored by University of Michigan Rogel Cancer Center. Started Oct 2014; status: completed.
02
Drugs
carfilzomib
03
Conditions
hematologic malignancygraft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02145403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02145403.